Outcome reporting in industry-sponsored trials of gabapentin for off-label use

Title

Outcome reporting in industry-sponsored trials of gabapentin for off-label use

Creator

Vedula SS; Bero L; Scherer RW; Dickersin K

Publisher

The New England Journal Of Medicine

Date

2009

Subject

Humans; Treatment Outcome; Clinical Protocols; Pain/drug therapy; Migraine Disorders/drug therapy; Randomized Controlled Trials as Topic/standards; Publication Bias; Bipolar Disorder/drug therapy; Hal's Folder; Amines/therapeutic use; Cyclohexanecarboxylic Acids/therapeutic use; gamma-Aminobutyric Acid/therapeutic use; Off-Label Use/statistics & numerical data; Outcome Assessment (Health Care)/methods/standards

Description

BACKGROUND: There is good evidence of selective outcome reporting in published reports of randomized trials. METHODS: We examined reporting practices for trials of gabapentin funded by Pfizer and Warner-Lambert's subsidiary, Parke-Davis (hereafter referred to as Pfizer and Parke-Davis) for off-label indications (prophylaxis against migraine and treatment of bipolar disorders, neuropathic pain, and nociceptive pain), comparing internal company documents with published reports. RESULTS: We identified 20 clinical trials for which internal documents were available from Pfizer and Parke-Davis; of these trials, 12 were reported in publications. For 8 of the 12 reported trials, the primary outcome defined in the published report differed from that described in the protocol. Sources of disagreement included the introduction of a new primary outcome (in the case of 6 trials), failure to distinguish between primary and secondary outcomes (2 trials), relegation of primary outcomes to secondary outcomes (2 trials), and failure to report one or more protocol-defined primary outcomes (5 trials). Trials that presented findings that were not significant (P > or = 0.05) for the protocol-defined primary outcome in the internal documents either were not reported in full or were reported with a changed primary outcome. The primary outcome was changed in the case of 5 of 8 published trials for which statistically significant differences favoring gabapentin were reported. Of the 21 primary outcomes described in the protocols of the published trials, 6 were not reported at all and 4 were reported as secondary outcomes. Of 28 primary outcomes described in the published reports, 12 were newly introduced. CONCLUSIONS: We identified selective outcome reporting for trials of off-label use of gabapentin. This practice threatens the validity of evidence for the effectiveness of off-label interventions.
2009

Rights

Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).

Type

Journal Article

Citation List Month

Backlog

Pages

1963-1971

Issue

20

Volume

361

Citation

Vedula SS; Bero L; Scherer RW; Dickersin K, “Outcome reporting in industry-sponsored trials of gabapentin for off-label use,” Pediatric Palliative Care Library, accessed January 23, 2022, https://pedpalascnetlibrary.omeka.net/items/show/14296.

Social Bookmarking